This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignees: Chugai Seiyaku Kabushiki Kaisha, Perseus Proteomics Inc., Other. Active years: 2015-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 987 
2 out of 28 
2 out of 834,570 Years Active: 2015-2017
As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide you with an article about inventor Masashi Fukayama based on the data provided.
Title: Masashi Fukayama: Innovating Cancer Diagnosis and Treatment Through ROBO1 Antibody
Introduction:
Masashi Fukayama, a distinguished inventor based in Tokyo, Japan, has contributed significantly to the field of cancer diagnosis and treatment. With a total of 2 patents to his name, Fukayama's innovative approach to utilizing anti-ROBO1 antibodies has revolutionized the way we combat cancer.
Latest Patents:
Fukayama's latest patents revolve around the utilization of anti-ROBO1 antibodies for cancer diagnosis and treatment. These patents outline methods for diagnosing cancer by detecting the ROBO1 protein and treating diseases caused by abnormal cell growth through the administration of antibodies that bind to ROBO1. Additionally, his patents detail techniques for inducing cell damage in ROBO1 expressing cells and monitoring the progression of hepatitis by detecting the ROBO1 protein.
Career Highlights:
Throughout his career, Masashi Fukayama has been instrumental in the advancement of cancer research. His dedication to developing innovative solutions for cancer diagnosis and treatment has garnered recognition within the scientific community. Fukayama has worked with reputable companies such as Perseus Proteomics Inc., where he further honed his skills and expertise in the field.
Collaborations:
Fukayama's collaborations with esteemed colleagues such as Hiroyuki Aburatani and Yoshitaka Hippo have been pivotal in his groundbreaking research endeavors. By working closely with other experts in the field, Fukayama has been able to push the boundaries of innovation and make significant strides in cancer treatment.
Conclusion:
In conclusion, Masashi Fukayama stands as a beacon of innovation in the realm of cancer diagnosis and treatment. His groundbreaking work with anti-ROBO1 antibodies showcases his commitment to revolutionizing the field and improving patient outcomes. With a strong track record of patents and collaborative efforts, Fukayama continues to inspire and drive advancements in the fight against cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile